US Patent 9,814,721 scope and claims: method-of-use protection for once-daily ~560 mg oral treatment of post–anti-CD20 marginal zone lymphoma
US 9,814,721 protects a specific clinical regimen for marginal zone lymphoma (MZL) after at least one prior anti-CD20 therapy, using an oral compound at about 560 mg once per day. The claim set is method-of-treatment focused (not composition) and narrows along three main axes: (i) patient population (post–anti-CD20), (ii) disease subtype (relapsed/refractory; extranodal MALT; nodal; splenic), and (iii) administration and outcome language (solid oral dose form; response/stable disease outcomes).
What is the core scope of US 9,814,721 claims?
Claim 1 is the anchor. It is framed as a method for treating MZL in an individual who has received at least one prior anti-CD20-based therapy, by administering an oral dose once per day of about 560 mg of a compound having a specified structure.
Key scope elements embedded in Claim 1:
- Indication: marginal zone lymphoma (MZL)
- Line of therapy constraint: at least one prior anti-CD20-based therapy
- Dosing regimen: once per day; about 560 mg; oral dose
- Drug identity: “a compound having the structure” (structure defines the chemical scope)
- Timing and regimen type: method-of-treatment by administration (no explicit duration, cycles, or retreatment windows in the excerpt)
Claim-interpretation levers that materially affect infringement
- “About 560 mg” dosing elasticity
- “About” generally expands literal scope to a tolerated range around 560 mg (during prosecution and construction, courts often use specification examples and intrinsic evidence). Operationally, the claim is designed to capture the marketed dose even if minor rounding exists.
- “Once per day”
- Enforces a once-daily dosing cadence. A twice-daily regimen would be less likely to read literally, though doctrine-of-equivalents arguments can still arise.
- “At least one prior anti-CD20-based therapy”
- Requires the treated patient to have a history of anti-CD20 exposure. For commercial and litigation analysis, this matters for patient selection, label wording, and how real-world prescribing is documented.
- “Compound having the structure”
- This makes the claim’s chemical boundaries central. Any change in the structure could avoid literal infringement, but process-dependent impurities and salts/co-crystals can complicate practical enforcement if the marketed drug is still the same “compound.”
What additional claim limitations narrow the US 9,814,721 patent estate?
Claims 2 to 11 build narrower sub-specifications off Claim 1.
H2: What subtypes of marginal zone lymphoma are covered (relapsed/refractory, extranodal MALT, nodal, splenic)?
Answer (from the claim text you provided):
- Claim 2: relapsed or refractory MZL
- Claim 3: extranodal marginal zone B cell lymphoma
- Claim 4: extranodal MZL-mucosa-associated lymphoid tissue (MALT) lymphoma
- Claim 5: nodal marginal zone B-cell lymphoma
- Claim 6: splenic marginal zone B-cell lymphoma
Practical consequence: The patent is positioned to cover the full MZL taxonomy after anti-CD20, capturing multiple clinical phenotypes under a single chemical/dosing backbone.
H2: What formulation and route-of-administration limitations exist in US 9,814,721?
- Claim 7: solid oral dosage form
- This narrows the claim to solid oral dosage forms (e.g., tablets/capsules/solid dispersions). Liquid oral formulations would be outside literal scope if they do not qualify as “solid.”
H2: What response and disease-progression language exists in the dependent claims?
Claims 8 to 11 specify outcome language:
- Claim 8: stable disease, partial response, or complete response
- Claim 9: partial response or complete response
- Claim 10: complete response
- Claim 11: no progressive disease
Infringement and proof impact
- Outcome-based limitations often raise evidentiary and causation questions in enforcement. However, because these are method claims for treatment, proof usually centers on clinical results in treated patients consistent with a course of therapy.
What does Claim 1 require for infringement under the provided scope?
To fall within Claim 1 literally, an accused regimen must satisfy all of the following simultaneously:
- The target patient has marginal zone lymphoma.
- The patient has received at least one prior anti-CD20-based therapy.
- The regimen administers the claimed structured compound.
- The administration is oral.
- The dosing is once per day.
- The dose is about 560 mg.
Any single missing element can defeat literal infringement of Claim 1.
What does this claim structure imply about the chemical and composition patent landscape?
This patent is a method-of-treatment claim set. Without the full bibliographic record of US 9,814,721, it is not possible to determine which other patents cover:
- the compound itself (composition-of-matter),
- specific salts/polymorphs/solid forms,
- manufacturing processes, or
- additional dosing schedules (e.g., different mg strengths or titration).
However, the claim text you provided strongly suggests the litigation “attack surface” is less about chemical identity alone and more about:
- patient selection (post–anti-CD20 MZL),
- dosing schedule (once-daily),
- dose amount (“about 560 mg”),
- route and dosage form (solid oral),
- and clinical endpoints (response/progression).
In practice, a robust estate for an oncology oral regimen commonly includes multiple layers: composition patents for the compound and derivatives, formulation patents, and separate method-of-use patents by indication and line of therapy. US 9,814,721 appears to belong to the method-of-use layer.
When does US 9,814,721 lose exclusivity?
No expiration date, priority date, patent term adjustment (PTA), patent term extension (PTE), or terminal disclaimer terms are provided in the prompt. Without those bibliographic details, a precise exclusivity timeline cannot be produced.
What are the generic entry risks for post–anti-CD20 marginal zone lymphoma once-daily ~560 mg oral therapy?
Because the protection is method-of-treatment focused, generic risk depends on labeling and prescribing behavior.
H2: What generic launch scenarios are most exposed under method-of-use claims?
- Scenario A: ANDA labeling mirrors the patented regimen
- If the generic’s proposed label explicitly claims treatment of MZL after anti-CD20 with once-daily oral dosing of ~560 mg, it is more likely to trigger direct infringement and/or induced infringement theories.
- Scenario B: carve-outs and “skinny label”
- If the generic omits the patented indication and/or line-of-therapy language, enforcement shifts toward indirect infringement or off-label prescribing arguments.
- Scenario C: dose differs materially
- If a generic uses a different daily dose strength or dosing frequency (e.g., twice daily), the “once per day” and “about 560 mg” limitations may be harder to meet literally.
H2: What manufacturing or dosage-form workarounds exist?
- Solid oral dosage form requirement
- If a generic uses a non-solid dosage route (unlikely for an oncology small-molecule but possible depending on formulation strategy), it could avoid Claim 7’s limitation.
- Dose form reformulation
- Even within “solid oral,” different solid forms are still typically considered within the method claim if the administered compound is the same and dosing matches.
What patent estate strength indicators can be inferred from Claim 1’s structure?
Even without the rest of the patent family, the claim is structured to be commercially meaningful:
- It is narrow enough to be patentable (specific post–anti-CD20 MZL setting and a defined oral dosing regimen).
- It has multiple dependent claims that track major clinical subtypes and standard response language used in oncology trial endpoints.
- It supports enforcement across multiple patient phenotypes under one compound/dose.
How does the claim language shape FDA regulatory and Orange Book dynamics?
H2: What is the Orange Book status of US 9,814,721 and how does that affect Paragraph IV risk?
No Orange Book listing details (drug name, NDA/BLA, listed patents, exclusivity codes) are provided in the prompt. Without the NDA/BLA and Orange Book data, a Paragraph IV/Orange Book status analysis cannot be completed.
What patent litigation affects US 9,814,721?
No lawsuit captions, parties, dates, settlements, or district court outcomes are provided in the prompt. Without that record, litigation-impact analysis cannot be completed.
How does US 9,814,721 compare with typical MZL post–anti-CD20 patent strategies?
In oncology method-of-use patenting, post–anti-CD20 MZL is commonly protected via:
- line-of-therapy dependent claims (post-exposure),
- indication/subtype dependent claims (extranodal, nodal, splenic; MALT),
- dosing regimen claims (dose amount and schedule),
- and response/progression endpoints.
US 9,814,721’s claim set aligns with that playbook: the independent claim anchors the regimen; dependents map it across clinical subtypes and endpoint language. That design increases the likelihood that real-world treatment patterns create at least one infringement path even if an accused regimen deviates on a single axis.
Key Takeaways
- Claim 1 is a regimen claim: oral compound at about 560 mg once daily to treat MZL after at least one prior anti-CD20-based therapy.
- Dependent claims broaden clinical coverage within the same regimen: relapsed/refractory; extranodal MALT; nodal; splenic.
- Dose-form constraint exists: solid oral dosage form (Claim 7).
- Outcome language is embedded: stable disease/response/no progression (Claims 8 to 11), which can matter for evidentiary proof in enforcement.
- Workaround space is limited by the claim’s combined requirements: changing patient selection (non–anti-CD20), dosing cadence, and/or dose amount, and potentially dosage form, are the main levers that could avoid literal reading.
FAQs
-
Does US 9,814,721 cover both relapsed/refractory and treatment-naïve MZL after anti-CD20?
Claim 1 covers MZL after prior anti-CD20; Claim 2 specifically adds relapsed/refractory.
-
Can a twice-daily oral regimen avoid Claim 1?
The claim requires “once per day,” so a twice-daily schedule would not meet the literal schedule limitation.
-
What happens if a patient received anti-CD20 but not immediately before the new MZL therapy?
The claim requires the patient “has received at least one prior anti-CD20-based therapy,” not immediate prior use.
-
Are non-solid oral formulations covered by Claim 7?
Claim 7 limits to “solid oral dosage form,” so non-solid oral routes would not satisfy that limitation.
-
Do Claims 8 to 11 require the treated patient to achieve the stated responses for infringement?
The dependent claims define the method by outcome language; enforcement would typically require evidence consistent with those clinical endpoints.
References
- US Patent 9,814,721. (Claims excerpt provided in prompt).
